Scholarlink

<p>Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as an effective strategy for stage III non-small cell lung cancer (NSCLC). However, predictive biomarkers of response remain limited. DNA polymerase epsilon (<i>POLE</i>) mutations, although rare in NSCLC, are associated with an increased tumor mutational burden and enhanced neoantigen presentation, both of which may promote immune sensitivity. A 52-year-old woman was diagnosed with stage IIIA NSCLC. Tumor programmed death-ligand 1 (PD-L1) expression was negative. Molecular profiling revealed a somatic <i>POLE</i> mutation (NM_006231.4 (<i>POLE</i>): c.1270C&gt;G (p.Leu424Val)), without additional tumor alterations. A perioperative chemo-immunotherapy approach was implemented. After three cycles of neoadjuvant carboplatin, pemetrexed, and pembrolizumab, computed tomography (CT) scan revealed a significant response. Then, the patient underwent to curative-intent surgery. Histopathological examination demonstrated a pathological complete response (pCR). Adjuvant pembrolizumab (thirteen cycles) was administered without relevant toxicities. At 18-month follow-up, the patient remained disease-free with good performance status. In conclusion, we report the case of pCR in a <i>POLE</i>-mutated NSCLC patient treated with perioperative chemo-immunotherapy. Incorporating a <i>POLE</i> evaluation could improve the integrated decision-making process for patients with NSCLC in the perioperative setting. Prospective studies are warranted to validate this observation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pathological complete response in a POLE-mutated non-small cell lung cancer patient treated with perioperative chemoimmunotherapy: a case report and review of the literature

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Luigi Liguori,
  • Rosario De Feo,
  • Lucia Santaniello,
  • Brigida Miranda,
  • Valentina Pagliara,
  • Giovanna Polcaro,
  • Alessandro Caputo,
  • Giulia Cattaneo,
  • Marco Ventin,
  • Alberto Servetto,
  • Cristina R. Ferrone,
  • Stefano Pepe,
  • Francesco Sabbatino

摘要

Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as an effective strategy for stage III non-small cell lung cancer (NSCLC). However, predictive biomarkers of response remain limited. DNA polymerase epsilon (POLE) mutations, although rare in NSCLC, are associated with an increased tumor mutational burden and enhanced neoantigen presentation, both of which may promote immune sensitivity. A 52-year-old woman was diagnosed with stage IIIA NSCLC. Tumor programmed death-ligand 1 (PD-L1) expression was negative. Molecular profiling revealed a somatic POLE mutation (NM_006231.4 (POLE): c.1270C>G (p.Leu424Val)), without additional tumor alterations. A perioperative chemo-immunotherapy approach was implemented. After three cycles of neoadjuvant carboplatin, pemetrexed, and pembrolizumab, computed tomography (CT) scan revealed a significant response. Then, the patient underwent to curative-intent surgery. Histopathological examination demonstrated a pathological complete response (pCR). Adjuvant pembrolizumab (thirteen cycles) was administered without relevant toxicities. At 18-month follow-up, the patient remained disease-free with good performance status. In conclusion, we report the case of pCR in a POLE-mutated NSCLC patient treated with perioperative chemo-immunotherapy. Incorporating a POLE evaluation could improve the integrated decision-making process for patients with NSCLC in the perioperative setting. Prospective studies are warranted to validate this observation.